Literature DB >> 11709716

Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells.

K Koniaras1, A R Cuddihy, H Christopoulos, A Hogg, M J O'Connell.   

Abstract

Cell cycle checkpoints are surveillance mechanisms that monitor and coordinate the order and fidelity of cell cycle events. When defects in the division program of a cell are detected, checkpoints prevent the pursuant cell cycle transition through regulation of the relevant cyclin-cdk complex(es). Checkpoints that respond to DNA damage have been described for the G1, S and G2 phases of the cell cycle. The p53 tumour suppressor is a key regulator of G1/S checkpoints, and can promote cell cycle delay or apoptosis in response to DNA damage. The importance of these events to cellular physiology is highlighted by the fact that tumours, in which p53 is frequently mutated, have widespread defects in the G1/S DNA damage checkpoints and a heightened level of genomic instability. G2/M DNA damage checkpoints have been defined by yeast genetics, though the genes in this response are conserved in mammals. We show here using biochemical and physiological assays that p53 is dispensable for a DNA damage checkpoint activated in the G2 phase of the cell cycle. Moreover, upregulation of p53 through serine 20 phosphorylation, does not occur in G2. Conversely, we show that the Chk1 protein kinase is essential for the human G2 DNA damage checkpoint. Importantly, inhibition of Chk1 in p53 deficient cells greatly sensitizes them to radiation, validating the hypothesis of targeting Chk1 in rational drug design and development for anti-cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709716     DOI: 10.1038/sj.onc.1204942

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage.

Authors:  Eugene S Kandel; Jennifer Skeen; Nathan Majewski; Antonio Di Cristofano; Pier Paolo Pandolfi; Claudine S Feliciano; Andrei Gartel; Nissim Hay
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  Regulation of Chk1 by its C-terminal domain.

Authors:  Ana Kosoy; Matthew J O'Connell
Journal:  Mol Biol Cell       Date:  2008-08-20       Impact factor: 4.138

3.  Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.

Authors:  Sejin Chung; Paris Vail; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Clin Cancer Res       Date:  2018-12-11       Impact factor: 12.531

4.  Oral administration of caffeine during voluntary exercise markedly decreases tissue fat and stimulates apoptosis and cyclin B1 in UVB-treated skin of hairless p53-knockout mice.

Authors:  Yourong Lou; Qingyun Peng; Bonnie Nolan; George C Wagner; Yaoping Lu
Journal:  Carcinogenesis       Date:  2009-11-19       Impact factor: 4.944

5.  A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.

Authors:  Oliver Riesterer; Fumihiko Matsumoto; Li Wang; Jessica Pickett; David Molkentine; Uma Giri; Luka Milas; Uma Raju
Journal:  Invest New Drugs       Date:  2009-12-22       Impact factor: 3.850

Review 6.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

7.  Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies.

Authors:  Arunee Hematulin; Sutiwan Meethang; Kitsana Utapom; Sopit Wongkham; Daniel Sagan
Journal:  Oncol Lett       Date:  2018-01-09       Impact factor: 2.967

Review 8.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 9.  Roles of Chk1 in cell biology and cancer therapy.

Authors:  Youwei Zhang; Tony Hunter
Journal:  Int J Cancer       Date:  2013-05-28       Impact factor: 7.396

10.  Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

Authors:  Yan Liu; Kevin Marks; Glenn S Cowley; Julian Carretero; Qingsong Liu; Thomas J F Nieland; Chunxiao Xu; Travis J Cohoon; Peng Gao; Yong Zhang; Zhao Chen; Abigail B Altabef; Jeremy H Tchaicha; Xiaoxu Wang; Sung Choe; Edward M Driggers; Jianming Zhang; Sean T Bailey; Norman E Sharpless; D Neil Hayes; Nirali M Patel; Pasi A Janne; Nabeel Bardeesy; Jeffrey A Engelman; Brendan D Manning; Reuben J Shaw; John M Asara; Ralph Scully; Alec Kimmelman; Lauren A Byers; Don L Gibbons; Ignacio I Wistuba; John V Heymach; David J Kwiatkowski; William Y Kim; Andrew L Kung; Nathanael S Gray; David E Root; Lewis C Cantley; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-05-28       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.